Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral envelope via a two-step mechanism, the ADCs effectively block viral entry—offering seven times better efficacy than existing approaches. Overall, the findings point towards a promising new direction for HIV treatment—targeting two viral sites with a single molecule.
Continue Reading this article here
